FY2025 EPS Estimates for Pharming Group Cut by HC Wainwright

Pharming Group (NASDAQ:PHAR) – Equities research analysts at HC Wainwright reduced their FY2025 earnings estimates for shares of Pharming Group in a research report issued on Tuesday, October 15th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $0.60 per share for the year, down from their prior forecast of $0.65. HC Wainwright currently has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.

Pharming Group Stock Performance

NASDAQ PHAR opened at $8.61 on Wednesday. The firm’s fifty day moving average price is $7.92 and its two-hundred day moving average price is $8.64. The stock has a market cap of $579.83 million, a PE ratio of -53.81 and a beta of 0.15. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same quarter in the prior year, the company earned $0.02 earnings per share.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.